Biotech companies raised $5.15 billion in the first quarter of 2012, about 15 percent less than the $6.07 billion raised in the first quarter last year. Public companies felt the pinch slightly more than private companies: The total amount raised by the former dropped about 16 percent compared to the same period last year, while the total amount raised by the latter dropped about 8 percent.